These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19239397)

  • 21. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.
    Fonseca VA; Handelsman Y; Staels B
    Diabetes Obes Metab; 2010 May; 12(5):384-92. PubMed ID: 20415686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus.
    Levy P
    Metab Syndr Relat Disord; 2010 Dec; 8 Suppl 1():S9-13. PubMed ID: 20946010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release.
    Hofmann AF
    Hepatology; 2011 May; 53(5):1784. PubMed ID: 21520190
    [No Abstract]   [Full Text] [Related]  

  • 24. Initial combination therapy with metformin plus colesevelam in drug-naïve Hispanic patients with early type 2 diabetes.
    Rosenstock J; Hernandez-Triana E; Handelsman Y; Misir S; Jones MR; Nagendran S
    Postgrad Med; 2012 Jul; 124(4):7-13. PubMed ID: 22913889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colesevelam: a new and improved bile acid sequestrant?
    Tziomalos K; Karagiannis A; Mikhailidis DP; Athyros VG
    Curr Pharm Des; 2013; 19(17):3115-23. PubMed ID: 23317402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review.
    Ooi CP; Loke SC
    Diabet Med; 2014 Jan; 31(1):2-14. PubMed ID: 24024701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent.
    Davidson MH; Dicklin MR; Maki KC; Kleinpell RM
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2663-71. PubMed ID: 11060828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.
    Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Apr; 24(4):995-1009. PubMed ID: 18291066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of colesevelam HCl in the treatment of elderly patients.
    Gavin JR; Jones MR; Ford DM; Truitt KE
    Drugs Aging; 2014 Jun; 31(6):461-70. PubMed ID: 24777691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome.
    Vega GL; Dunn FL; Grundy SM
    Am J Cardiol; 2011 Oct; 108(8):1129-35. PubMed ID: 21813109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study.
    Handelsman Y; Goldberg RB; Garvey WT; Fonseca VA; Rosenstock J; Jones MR; Lai YL; Jin X; Misir S; Nagendran S; Abby SL
    Endocr Pract; 2010; 16(4):617-28. PubMed ID: 20634176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus.
    Henry RR; Aroda VR; Mudaliar S; Garvey WT; Chou HS; Jones MR
    Diabetes Obes Metab; 2012 Jan; 14(1):40-6. PubMed ID: 21831167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus.
    Sonnett TE; Levien TL; Neumiller JJ; Gates BJ; Setter SM
    Clin Ther; 2009 Feb; 31(2):245-59. PubMed ID: 19302898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of anti-diabetic drugs on LDL subclasses: any role for colesevelam?
    Rizzo M; Mikhailidis DP; Al-Rasadi K
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):205-7. PubMed ID: 24867816
    [No Abstract]   [Full Text] [Related]  

  • 35. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia.
    Stein EA; Marais AD; Szamosi T; Raal FJ; Schurr D; Urbina EM; Hopkins PN; Karki S; Xu J; Misir S; Melino M
    J Pediatr; 2010 Feb; 156(2):231-6.e1-3. PubMed ID: 19879596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol).
    Mazze RS; Strock ES; Monk AM; Murphy MM; Xi M; Bergenstal RM
    Endocr Pract; 2013; 19(2):275-83. PubMed ID: 23598534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes.
    Nerild HH; Christensen MB; Knop FK; Brønden A
    Expert Opin Drug Discov; 2018 Dec; 13(12):1161-1167. PubMed ID: 30336707
    [No Abstract]   [Full Text] [Related]  

  • 38. Colesevelam hydrochloride: a novel bile acid-binding resin.
    Aldridge MA; Ito MK
    Ann Pharmacother; 2001; 35(7-8):898-907. PubMed ID: 11485143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
    Perry CM
    Paediatr Drugs; 2010 Apr; 12(2):133-40. PubMed ID: 20218749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of bile acid sequestrants in the management of type 2 diabetes mellitus.
    Ganda OP
    Metab Syndr Relat Disord; 2010 Dec; 8 Suppl 1(Suppl 1):S15-21. PubMed ID: 21034179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.